HRP990416B1 - Pharmaceutical compositions containing eletriptan hemisulphate and caffeine - Google Patents

Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Info

Publication number
HRP990416B1
HRP990416B1 HR970276A HRP990416A HRP990416B1 HR P990416 B1 HRP990416 B1 HR P990416B1 HR 970276 A HR970276 A HR 970276A HR P990416 A HRP990416 A HR P990416A HR P990416 B1 HRP990416 B1 HR P990416B1
Authority
HR
Croatia
Prior art keywords
caffeine
pharmaceutical compositions
compositions containing
pct
eletriptan hemisulphate
Prior art date
Application number
HR970276A
Other languages
English (en)
Inventor
Valerie Denise Harding
Anne Billotte
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of HRP990416A2 publication Critical patent/HRP990416A2/hr
Publication of HRP990416B1 publication Critical patent/HRP990416B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR970276A 1997-07-03 1999-12-30 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine HRP990416B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions
PCT/EP1998/004176 WO1999001135A1 (en) 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Publications (2)

Publication Number Publication Date
HRP990416A2 HRP990416A2 (en) 2000-04-30
HRP990416B1 true HRP990416B1 (en) 2002-04-30

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970276A HRP990416B1 (en) 1997-07-03 1999-12-30 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Country Status (31)

Country Link
US (1) US6166025A (xx)
EP (1) EP0999841B1 (xx)
JP (1) JP3350061B2 (xx)
CN (1) CN1145486C (xx)
AT (1) ATE206921T1 (xx)
AU (1) AU724728B2 (xx)
BG (1) BG103930A (xx)
BR (1) BR9810658A (xx)
CA (1) CA2292673C (xx)
DE (1) DE69802097T2 (xx)
DK (1) DK0999841T3 (xx)
DZ (1) DZ2549A1 (xx)
EA (1) EA002174B1 (xx)
ES (1) ES2163291T3 (xx)
HK (1) HK1029282A1 (xx)
HR (1) HRP990416B1 (xx)
HU (1) HUP0004468A3 (xx)
ID (1) ID24528A (xx)
IL (1) IL133206A0 (xx)
IS (1) IS5283A (xx)
MA (1) MA26518A1 (xx)
NO (1) NO312993B1 (xx)
NZ (1) NZ501419A (xx)
OA (1) OA11227A (xx)
PL (1) PL337803A1 (xx)
PT (1) PT999841E (xx)
SI (1) SI0999841T1 (xx)
SK (1) SK284462B6 (xx)
TR (1) TR199903332T2 (xx)
UY (1) UY25078A1 (xx)
WO (1) WO1999001135A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
AU4799700A (en) 1999-04-27 2000-11-10 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
CN101076325A (zh) * 2004-10-22 2007-11-21 萧兴仁 含可食用羧酸和/或其酸性盐与咖啡碱的药物组合物以及无毒瘾性咖啡
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US20070111964A1 (en) 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP5776355B2 (ja) * 2010-07-16 2015-09-09 大正製薬株式会社 内服液剤
US8915245B2 (en) 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
WO2014143453A1 (en) * 2013-03-15 2014-09-18 Henkin Robert I Phosphodiesterase inhibitor treatment
EP3488889A1 (en) 2013-08-08 2019-05-29 Vapotherm, Inc. Respiratory therapy condensation adaptor
NL1040474C2 (en) * 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
BR9810658A (pt) 2000-10-03
SK284462B6 (sk) 2005-04-01
DE69802097D1 (de) 2001-11-22
CN1145486C (zh) 2004-04-14
CN1261279A (zh) 2000-07-26
AU8856998A (en) 1999-01-25
EP0999841B1 (en) 2001-10-17
NO312993B1 (no) 2002-07-29
CA2292673A1 (en) 1999-01-14
IL133206A0 (en) 2001-03-19
HUP0004468A2 (hu) 2001-10-28
NO995887L (no) 2000-03-02
HK1029282A1 (en) 2001-03-30
ES2163291T3 (es) 2002-01-16
EA002174B1 (ru) 2002-02-28
EP0999841A1 (en) 2000-05-17
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01
TR199903332T2 (xx) 2000-09-21
DK0999841T3 (da) 2001-11-19
HRP990416A2 (en) 2000-04-30
WO1999001135A1 (en) 1999-01-14
AU724728B2 (en) 2000-09-28
SI0999841T1 (xx) 2001-12-31
NZ501419A (en) 2000-09-29
DZ2549A1 (fr) 2003-02-08
HUP0004468A3 (en) 2004-07-28
UY25078A1 (es) 2000-12-29
PL337803A1 (en) 2000-09-11
JP3350061B2 (ja) 2002-11-25
EA199901100A1 (ru) 2000-08-28
DE69802097T2 (de) 2002-03-14
ATE206921T1 (de) 2001-11-15
SK182899A3 (en) 2000-09-12
BG103930A (en) 2000-07-31
PT999841E (pt) 2002-02-28
CA2292673C (en) 2003-04-22
OA11227A (en) 2003-07-18
IS5283A (is) 1999-11-30
ID24528A (id) 2000-07-20
US6166025A (en) 2000-12-26
JP2000516262A (ja) 2000-12-05

Similar Documents

Publication Publication Date Title
HK1029282A1 (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine.
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
ATE219765T1 (de) Indolderivate als cgmp-pde inhibitoren
IL134112A0 (en) Triazolo [4,5-d] pyrimidine compounds, their use anovel compounds s medicaments, compositions containing them and processes for their preparation
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MX9702865A (es) Agentes estrogenicos.
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
ZA971279B (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
WO1998001440A3 (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
MY119643A (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
ECSP982578A (es) Composiciones farmaceuticas que contienen eletriptan hemisulfato

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060101

Year of fee payment: 8

PBON Lapse due to non-payment of renewal fee

Effective date: 20060702